1

The Government Bioscience Grant (GBG) report is produced each month and is available at www.biosciencefunding.com.

For more information on non-dilutive government funding opportunities, please contact (216) 658-3995 or www.G2Gconsulting.com.

Government Bioscience Grant (GBG) Report – July 2015

Title (Agency) Opp.

Number

Description Deadline Funding Level Eligibility Link

BROAD AGENCY ANNOUNCEMENTS

Defense

Sciences Office-

wide BAA

DARPA-

BAA-15-

39

This BAA solicits executive summaries, abstracts and

proposals for revolutionary research efforts applicable to

the DSO mission. The mission of the Defense

Advanced Research Projects Agency (DARPA) Defense

Sciences Office (DSO) is to identify and pursue high-

risk, high-payoff research initiatives across a broad

spectrum of science and engineering disciplines and to

transform these initiatives into important, radically new,

game-changing technologies for U.S. national security.

6/30/16 N/A Unrestricted http://www.

darpa.mil/w

ork-with-

us/opportuni

ties

NEURAL SYSTEMS

Neurodevelopm

ental

Assessment of

Infants and

Children in

Resource-

Limited Settings

RFA-

HD-16-

024

This Funding Opportunity Announcement (FOA) invites

SBIR applications from small business concerns (SBCs)

to propose research to develop tools and/or materials for

neurodevelopmental assessment of cognitive

functioning of infants and children in resource-limited

settings.

Letter of

Intent:

8/14/15

Full

submission:

9/14/15

Est. Total

Program

Funding:

$1,500,000

Small

businesses

http://grants

.nih.gov/gra

nts/guide/rfa

-files/RFA-

HD-16-

024.html

2

NINDS Morris

K. Udall

Centers of

Excellence for

Parkinson’s

Disease

Research

(P50)(HHS,NIH

)

RFA-NS-

16-002

The overarching goal of the specialized Udall Centers

program is to establish a network of Centers that work

collaboratively as well as independently to define the

causes of and discover improved treatments for

Parkinson’s disease (PD). A more immediate goal for

each Center is to rapidly advance synergistic,

interdisciplinary research programs while serving as

national leaders in PD research. Udall Centers also serve

as local resources by organizing research career

enhancement activities for Center investigators and

periodic outreach to the PD patient/advocacy

community. Applicants are expected to identify and

address an overall research theme that defines a critical

challenge in PD research.

12/15/15 Estimated

Total Funding:

$1,500,000 for

one award

(Contingent

upon NIH

appropriations)

Unrestricted http://grants

.nih.gov/gra

nts/guide/rfa

-files/RFA-

NS-16-

002.html

DoD FY15 Peer

Reviewed

Alzheimer’s

Convergence

Science

Research Award

(USAMRAA)

W81XW

H-15-

PRARP-

CSRA

The intent of the FY15 CSRA is to support efforts to

generate research resources, tools, or novel research

efforts for researchers and/or practitioners in health

sciences related to the PRARP’s mission. The research

impact will benefit the military, Veteran, and civilian

communities.

The CSRA is open to Principal Investigators (PIs) at or

above the level of Assistant Professor (or equivalent)

from any field or discipline who seek to bring their

expertise to address the PRARP’s mission. However, as

part of the application, the PI should demonstrate that

the study team has experience in both TBI and AD

research. Preliminary data, while not required, is

encouraged.

11/25/15 Estimated

Total Program

Funding:

$2,800,000

Total direct and

indirect costs

should not

exceed

$500,000.

Unrestricted http://cdmrp

.army.mil/p

ubs/press/20

15/15prarpp

reann.shtml

3

DoD FY15 Peer

Reviewed

Alzheimer’s

Military Risk

Factors

Research Award

(USAMRAA)

W81XW

H-15-

PRARP-

MRFA

The intent of the FY15 MRFA is to facilitate high-

impact, systematic, population-based research

investigating the association between TBI and the

subsequent development of AD. The research impact

will benefit the military, Veteran, and civilian

communities. Applications should describe how the

association of TBI and subsequent AD will be

characterized. Applications should carefully consider

how their studies will characterize the cognitive and

behavioral symptoms that result in functional

impairments in the proposed cohort. Studies that use

combinations of measures (e.g., neuropsychological

assessments, imaging, genomics, and cerebral spinal

fluid biomarkers) are encouraged. Applications that

develop interdisciplinary teams or consortia as part of

the support plan for executing the research are

encouraged.

11/25/15 Estimated

Total Program

Funding:

$5,000,000

Maximum

funding of

$5,000,000 for

total costs

Unrestricted http://cdmrp

.army.mil/p

ubs/press/20

15/15prarpp

reann.shtml

NANOTECHNOLOGY

Nanomaterials

Health

Implications

Research

(NHIR):

Comprehensive

Evaluation of

Interactions

Between

Engineered

Nanomaterials

and Biological

System

(U01)(HHS,NI

H)

RFA-ES-

15-013

These research projects will investigate interactions

between ENMs and biological systems to generate

comprehensive biological response profiles for ENMs

that will be provided by Engineered nanomaterials

Resource and Coordination Core (ERCC) being

solicited through a companion FOA (RFA-ES-15-012).

This consortium will generate biological response

profiles for a select set of ENMs representing the

landscape of nanotechnology applications. The research

projects to be funded through this FOA will contribute

to long-range goals of the NIEHS Nano EHS program,

i.e., to derive detailed molecular, biochemical and

pathophysiological characterization of ENMs-biological

interactions as influenced by physicochemical properties

of ENMs.

11/30/15 Estimated

Total Program

Funding:

$3,000,000

Award Ceiling:

$300,000

Small

Businesses,

Public and

Private

institutions of

higher

education,

nonprofits,

government

entities

http://grants

.nih.gov/gra

nts/guide/rfa

-files/RFA-

ES-15-

013.html

4

THERAPEUTICS

Pre-application:

Opportunities

for

Collaborative

Research at the

NIH Clinical

Center

(X02)(NIH)

PAR-13-

357

This program seeks to broaden and strengthen

translational research collaborations between basic and

clinical researchers both within and outside NIH to

accelerate and enhance translational science by

promoting partnerships between NIH intramural

investigators (e.g., those conducting research within the

labs and clinics of the NIH) and extramural

investigators (e.g., those conducting research in labs

outside the NIH), and by providing support for

extramural investigators to take advantage of the unique

research opportunities available at the NIH Clinical

Center by conducting research projects in collaboration

with NIH intramural investigators.

12/15/17 N/A –

Collaboration

Award

Unrestricted http://grants

.nih.gov/gra

nts/guide/pa

-files/PAR-

15-286.html

DoD Military

Burn Injuries

Research Award

(USAMRAA)

W81XW

H-15-

MBRP-

BIRA

The objective of this FOA is to explore innovative

approaches to accelerate the translation of advances in

knowledge into new treatments of the injured Service

member who sustains burn injuries. The results of the

research funded through the FY15 MBRP Burn Injuries

Research Award are expected to increase the body of

knowledge and products available to professionals and

practitioners in health, medical science, and related

fields. The research impact is expected to benefit both

civilian and military communities. To be considered for

funding, each application of the FY15 MBRP Burn

Injuries Research Award must address one – and only

one – of the following Topic Areas: 1) Fluid

Resuscitation (Human); 2) Organ Failure Studies

(Human); 3) Wound Healing (Animal/Human).

12/3/15 Estimated

Total Program

Funding:

$8,000,000

Funding Level

1: Total direct

and indirect

costs should

not exceed

$750,000.

Funding Level

2: Total direct

and indirect

costs should

not exceed

$2,000,000.

Unrestricted http://cdmrp

.army.mil/fu

nding/pa/15

mbrpbira_p

a.pdf

5

ORTHOPEDICS, ORTHOTICS

DoD Peer

Reviewed

Orthopaedic

Applied

Research Award

(USAMRAA)

W81XW

H-15-

PROP-

ARA

The PRORP Applied Research Award seeks applied

research applications focused on advancing optimal

treatment and restoration of function for military

personnel with musculoskeletal injuries sustained during

combat or combat-related activities. It is expected that

any research findings would also provide benefit to the

general population. The FY15 PRORP ARA is focused

on applied research, defined as work that refines

concepts and ideas into potential solutions with a view

toward evaluating technical feasibility of promising new

products, pharmacologic agents, behavioral and

rehabilitation interventions, diagnostic and therapeutic

techniques, clinical guidance, and/or emerging

approaches and technologies. Upon successful

completion, these studies are expected to yield potential

health products, approaches, or technologies positioned

for human testing. Presentation of preliminary data is

required. Inclusion of preliminary and/or published data

relevant to the research question is required.

11/19/15 Estimated

Total Program

Funding:

$3,000,000

Funding Level

1: Total direct

and indirect

costs should

not exceed

$500,000.

Funding Level

2: Total direct

and indirect

costs should

not exceed

$1,000,000.

Unrestricted http://cdmrp

.army.mil/fu

nding/pa/15

prorpara_pa

.pdf

DoD FY15

Prosthetics

Outcomes

Research Award

(USAMRAA)

W81XW

H-15-

OPORP-

PORA

The FY15 Prosthetics Outcomes Research Award is

intended to support research that evaluates the

comparative effectiveness of prosthetic clinical

interventions, and/or their associated rehabilitation

interventions, using patient-centric outcomes for Service

members and Veterans who have undergone limb

impairment or limb amputation. The objective is to

improve the understanding of prosthetic devices,

treatments, rehabilitation strategies, and secondary

health effects. The ultimate goal is to advance the

adoption and implementation of these evidence-based

interventions. Proposed projects should be designed to

provide patient-centric outcomes data regarding

prosthetic devices, and/or related clinical interventions

and must include the anticipated effect on patient care

metrics.

11/16/16 Funding Level

1: Total direct

and indirect

costs should

not exceed

$500,000.

Funding Level

2: Total direct

and indirect

costs should be

between

$500,000 and

$2,500,000.

Unrestricted http://cdmrp

.army.mil/fu

nding/pa/15

oporppora_

pa.pdf

6

DoD Peer

Reviewed

Orthopaedic

Clinical Trial

Award

(USAMRAA)

W81XW

H-15-

PRORP-

CTA

The PRORP Clinical Trial Award supports the rapid

implementation of clinical trials with the potential to

have a major impact on military combat-related

orthopaedic injuries, or non-battle injuries that

significantly impact unit readiness and return-to-

duty/work rates. The clinical trials may be designed to

evaluate promising new products, pharmacologic agents

(drugs or biologics), devices, clinical guidance, and/or

emerging approaches and technologies. All applications

are required to articulate the relevance of the proposed

project to military and/or Veteran populations affected

by orthopaedic injury. Collaboration with military

researchers and clinicians is encouraged, and studies

that include active duty military or Veteran participants

as all or a portion of the study population will be

considered.

11/19/15 Estimated

Total Program

Funding:

$6,000,000

Total direct and

indirect costs

should not

exceed

$3,000,000.

Unrestricted http://cdmrp

.army.mil/fu

nding/pa/15

prorpcta_pa.

pdf

DoD FY15

Orthotics

Outcomes

Research Award

(USAMRAA)

W81XW

H-15-

OPORP-

OORA

The FY15 Orthotics Outcomes Research Award is

intended to support research that evaluates the

comparative effectiveness of orthotic clinical

interventions and/or their associated rehabilitation

interventions, using patient-centric outcomes for Service

members and Veterans who have undergone limb

impairment or limb amputation. The objective is to

improve the understanding of orthotic devices,

treatments, rehabilitation strategies, and secondary

health effects. The ultimate goal is to advance the

adoption and implementation of these evidence-based

interventions. Proposed projects should be designed to

provide patient-centric outcomes data regarding orthotic

devices, and/or related clinical interventions, and must

include the anticipated effect on patient care metrics.

Principal Investigators (PIs) are strongly encouraged to

collaborate, integrate, and/or align their research

projects with Department of Defense (DoD) and/or VA

research laboratories and programs. All applications

must demonstrate direct relevance to Service members

and Veterans with traumatic extremity injury and/or

amputation using orthotic devices.

11/16/15 Estimated

Total Program

Funding:

$4,500,000

Funding Level

1: Total direct

and indirect

costs should

not exceed

$500,000.

Funding Level

2: Total direct

and indirect

cost should be

between

$500,000 and

$2,500,000

Unrestricted http://cdmrp

.army.mil/fu

nding/pa/15

oporpoora_

pa.pdf

7

CANCER

Utilizing the

PLCO

Biospecimens

Resource to

Bridge Gaps in

Cancer Etiology

and Early

Detection

Research (U01)

PAR-15-

297

This FOA encourages the submission of applications

that propose to advance research in cancer etiology and

early detection biomarkers, utilizing the advantages of

the unique biorepository resources of the NCI-

sponsored Prostate, Lung, Colorectal, and Ovarian

Cancer (PLCO) Screening Trial. The PLCO

Biorepository offers high-quality, prospectively

collected, serial pre-diagnostic blood samples from the

PLCO screened arm participants, and a onetime

collection of buccal cells from the control arm

participants. Available data associated with the

biospecimens includes demographic, diet, lifestyle,

smoking, screening results, and clinical data. This FOA

supports a wide range of cancer research including, but

not limited to, biochemical and genetic analyses of

cancer risk, as well as discovery and validation of early

detection biomarkers. The proposed research project

must involve use of PLCO biospecimens; additionally,

it should also take advantage of the unique

characteristics of the PLCO biospecimens. Research

projects that do not involve the use of PLCO

biospecimens will not be supported under this FOA.

8/15/18 Application

budgets are not

limited but

need to reflect

the actual

needs of the

proposed

project.

Unrestricted http://grants

.nih.gov/gra

nts/guide/pa

-files/PAR-

15-

297.html#_

Section_II._

Award_1

DoD Prostate

Cancer Idea

Development

Award

(USAMRAA)

W81XW

H-15-

PCRP-

IDA

The mission of the FY15 PCRP is to find and fund

research that will lead to the elimination of death from

prostate cancer and enhance the well-being of men

experiencing the impact of the disease. Specifically, the

PCRP seeks to promote highly innovative,

groundbreaking research; high-impact research with

near-term clinical relevance; multidisciplinary,

synergistic research; translational studies to support the

fluid transfer of knowledge between bedside and bench;

research on patient survivorship and quality of life; the

next generation of prostate cancer investigators through

mentored research; and research on disparities in the

incidence and mortality of prostate cancer.

9/24/15 Total direct and

indirect costs

should not

exceed

$375,000 for

Established

Investigators;

$250,000 for

New

Investigators;

$750,000 for

Partnering

Investigators.

Unrestricted http://cdmrp

.army.mil/fu

nding/pa/15

pcrpida_pa.

pdf

8

The Pancreatic

Cancer

Detection

Consortium

(U01)(HHS,NI

H)

PAR-15-

289

This FOA invites applications from multi-disciplinary

teams of researchers and clinicians to establish the

Pancreatic Cancer Detection Consortium (PCDC) to

conduct research to improve the detection of early stage

pancreatic ductal adenocarcinoma (PDAC) and

characterization of its precursor lesions. The PCDC is

intended to support research for the development and

testing of new molecular and imaging biomarkers for

identifying patients at high risk for PDAC (because of

genetic factors or the presence of precursor lesions) who

could be candidates for early intervention. The research

will be conducted by individual multi-disciplinary

research teams, hereafter called Units. The Units will

undertake studies on the following areas: identification

and testing of biomarkers measurable in bodily fluids

for early detection of PDAC or its precursor lesions;

determine which pancreatic cysts are likely to progress

to cancer; develop molecular- and/or imaging-based

approaches for screening populations at high risk of

PDAC; conduct biomarker validation studies; and

collect longitudinal biospecimens for the establishment

of a biorepository. All Units are expected to participate

in collaborative activities with other Units and share

ideas, specimens and data within the Consortium.

4/6/18 The number of

awards is

contingent

upon NIH

appropriations

and the

submission of a

sufficient

number of

meritorious

applications.

Unrestricted http://grants

.nih.gov/gra

nts/guide/pa

-files/PAR-

15-289.html

DoD Peer

Reviewed

Cancer Horizon

Award

W81XW

H-15-

PRCRP-

HA

The Horizon Award supports junior level scientists to

conduct impactful research with the mentorship of an

experienced cancer researcher (Mentor). The Horizon

Award challenges junior scientists to develop and

implement research in the cancer field. This opportunity

allows for junior investigators to develop a research

project, investigate a problem or question in the field of

cancer, and further their intellectual development as a

cancer researcher of the future. Under this award

mechanism, the junior investigator is considered the

Principal Investigator (PI), and the application should

focus on the PI’s research and career development. It

should be clear that the proposed research is

intellectually designed by the PI with assistance from

the Mentor. Preliminary data are not required.

Pre-

Application:

8/11/15

Full

submission:

9/29/15

Est. Total

Program

Funding:

$1,560,000

Unrestricted http://cdmrp

.army.mil/fu

nding/pa/15

prcrpha_pa.

pdf

9

DIGESTIVE DISEASES

Exploratory

Studies for

Delineating

Microbiome:

Host

Interactions in

Obesity,

Digestive and

Liver Diseases

and Nutrition

(R21)(HHS,

NIH)

RFA-

DK-15-

013

This FOA invites applications that explore and

interrogate functional interactions between human gut

microbiome and host interactions in obesity, digestive

and liver diseases, and nutrition.

10/19/16

Award Ceiling:

$200,000

Total Program

Funding:

$1,500,000

Unrestricted http://grants

.nih.gov/gra

nts/guide/rfa

-files/RFA-

DK-15-

013.html

Community

Research

Resource of

Microbiome-

Derived Factors

Modulating

Host Physiology

in Obesity,

Digestive and

Liver Diseases,

and Nutrition

(R24)(HHS,

NIH)

RFA-

DK-15-

012

The purpose of this FOA is to invite applications from

multidisciplinary research teams to create a community

research resource of key members of the microbiota and

factors they elaborate which modulate host physiology

and pathophysiology related to obesity, nutrition, or

liver, exocrine pancreatic, or digestive diseases, and to

disseminate it broadly to the research community, in

order to advance the development of microbiome-based

interventions for prevention and treatment of these

diseases. The resource will include annotated genome

sequences and cultures of the key microbes, chemical

structures of the key compounds they elaborate, datasets

used to identify key microbes and compounds, and

software for novel analytic methods developed to enable

their identification.

10/19/16 NIDDK

intends to

commit $ 6

million in

FY16 and

FY17 to fund

2-4 awards.

Unrestricted http://grants

.nih.gov/gra

nts/guide/rfa

-files/RFA-

DK-15-

012.html

10

GENETICS

Mechanisms

Underlying the

Contribution of

Type 1 Diabetes

Risk Associated

Variants (DP3)

RFA-

DK-15-

025

This Funding Opportunity Announcement (FOA)

encourages research project grant applications from

institutions/organizations for projects to characterize the

genetic variations in human genomic regions that have

been putatively associated with type 1 diabetes (T1D)

and conduct follow-up functional studies of particular

genetic variants. In addition there are many human T1D

regions for which there is no compelling functional

candidate gene and thus additional work to identify

causal genes and potential causal variants and elucidate

the mechanisms whereby changes in the function or

regulation of these genes are likely to provide crucial

new insights into disease pathogenesis are also

encouraged.

Letter of

Intent:

1/17/16

Full

submission:

2/17/16

Est Total

Program

Funding:

$15,000,000

Award ceiling:

$600,000

Unrestricted http://grants

.nih.gov/gra

nts/guide/rfa

-files/RFA-

DK-15-

025.html

GENERAL

Collaborative

Projects to

Accelerate

Research in

Organ Fibrosis

(R01)

RFA-HL-

16-003

While fibrogenesis is an essential process in normal

wound healing, aberrant and relentless fibrogenesis in

vital organs such as heart, lung, kidney, and bone

marrow can lead to debilitating symptoms and organ

failure. Aberrant fibrogenesis at the cellular level shows

remarkable similarities across different organ systems.

Moreover, a disease such as systemic sclerosis or an

injury such as ionizing radiation may cause fibrosis in

more than one organ system. Thus, collaborations

among researchers studying fibrosis in different organ

systems may greatly accelerate research in this area.

This Funding Opportunity Announcement (FOA) invites

Research Project Grant (R01) applications from

collaborating investigators to characterize and compare

mechanisms of aberrant fibrogenesis and/or fibrosis

resolution in different organ systems; develop novel

therapeutic strategies aimed to lessen organ fibrosis; or

develop novel technologies to study fibrosis.

10/21/16 Award ceiling:

$350,000

Unrestricted http://grants

.nih.gov/gra

nts/guide/rfa

-files/RFA-

HL-16-

003.html

11

Direct Phase II

SBIR Grants to

Support

Extended

Development,

Hardening, and

Dissemination

of Technologies

in Biomedical

Computing,

Informatics, and

Big Data

Science (R44)

PAR-15-

288

This FOA encourages SBIR grant applications from

small business concerns (SBCs) that propose the

extended development, maintenance, testing, evaluation,

hardening and dissemination of existing biomedical

software. This FOA is for applications that have

completed the proof of concept Phase I stage-type of

research through other (non-SBIR) funding sources. The

NIH is interested in promoting a broad base of research

and development of a broad base of innovative

technologies in biomedical computing, informatics, and

Big Data Science that will support rapid progress in

areas of scientific opportunity in biomedical research. It

is expected that this research and development is

conducted in the context of important biomedical and

behavioral research problems. As such, applications are

intended to develop enabling technologies that could

apply to the interests of most NIH Institutes and Centers

and range from basic biomedicine to research in all

relevant organ systems and diseases.

4/5/17 Total funding

support

normally may

not exceed

$1,000,000 for

Phase II awards

Small

businesses

http://grants

.nih.gov/gra

nts/guide/pa

-files/PAR-

15-288.html

Small Business

Innovation

Research

Program Phase I

USDA-

NIFA-

SBIR-

005277

Proposed Phase I projects should prove the scientific or

technical feasibility of the approach or concept. Projects

dealing with agriculturally related manufacturing and

alternative and renewable energy technologies are

encouraged across all SBIR topic areas. USDA SBIR's

flexible research areas ensure innovative projects

consistent with USDA's vision of a healthy and

productive nation in harmony with the land, air, and

water. USDA SBIR Program has awarded over 2000

research and development projects since 1983, allowing

hundreds of small businesses to explore their

technological potential, and providing an incentive to

profit from the commercialization of innovative ideas.

10/8/15 Est. Total

Program

Funding:

$9,000,000

Small

Businesses

http://nifa.u

sda.gov/fun

ding-

opportunity/

small-

business-

innovation-

research-

program-

phase-i

12

Non- or

Minimally-

Invasive

Methods to

Measure

Biochemical

Substances for

Neonatal and

Perinatal

Clinical Care

and Research

(R41)(HHS,

NIH)

RFA-

HD-16-

028

The primary purpose of this initiative is to stimulate

translational research by inviting small businesses with

bioengineering and biomedical expertise to collaborate

to develop advanced, non- or minimally invasive

methods for rapid measurement and monitoring of

biochemical substances during the care of perinatal and

pediatric patient populations. The methods should

provide reliable measurements of commonly assessed

biochemical substances helping maternal and neonatal

patient care, including neonatal intensive care. The

primary aim of this line of research is to develop

approaches to reduce or eliminate pain and discomfort

associated with obtaining blood or other products for

clinical care and research in perinatal, neonatal, and

pediatric patient populations.

The second objective of the FOA is to invite the

bioengineering and biomedical scientists to develop lab-

on-a-chip methods to measure biomarkers that could be

applied for diagnostic and prognostic purposes during

perinatal patient care and in clinical and translational

research studies. The patient populations in which these

can be used are pregnant and lactating women, newborn

infants, and children of all ages.

8/24/15

NICHD intends

to commit

$1,000,000 in

FY 2016 to

fund 4-8 new

awards.

Small

Businesses

http://grants

.nih.gov/gra

nts/guide/rfa

-files/RFA-

HD-16-

028.html

Bioengineering

Research

Partnership

(BRP): Non- or

Minimally-

Invasive

Methods to

Measure

Biochemical

Substances

during Neonatal

and Perinatal

Patient Care and

Research

(R01)(NIH)

The goal for a Bioengineering Research Partnership

(BRP) is to drive the development and speed the

adoption of promising tools and technologies that can

address important biomedical research problems for

which there is a scarcity of solutions. The use of

engineering principles is encouraged to establish these

tools and technologies as robust, well-characterized

solutions that fulfill an unmet need. A synergistic

partnership between the engineering, and biomedical

professions is required, where the unique skills of each

discipline combine to enhance our understanding of life

science processes or the practice of medicine.

1/17/18

Collaboration

Opportunity

Unrestricted http://grants

.nih.gov/gra

nts/guide/pa

-files/PAR-

15-285.html

13

Exploration of

the Roles of

Brown and

Beige Adipose

Tissue in

Humans

(R01)(HHS,

NIH)

RFA-

DK-15-

031

This FOA invites applications for Research Project

Grants (R01) to investigate the biological functions of

brown and beige adipose tissue in humans, other than

heat production and maintenance of body temperature,

and to explore their impact on human health.

Specifically, it seeks to 1) identify physiologic or

pathophysiologic conditions other than prolonged cold

exposure under which browning of human subcutaneous

or other white adipose depots occurs, or where the

brown adipose tissue depot found in the neck region is

expanded through browning; 2) test potential non-

biopsy biomarkers of human subcutaneous beige fat and

3) explore the biological functions of human brown and

beige fat.

3/9/16

NIDDK

intends to

commit up to

$2,000,000 in

FY2016 to

fund 3 to 6

awards. Future

year amounts

will depend on

annual

appropriations.

Unrestricted http://grants

.nih.gov/gra

nts/guide/rfa

-files/RFA-

DK-15-

031.html

The Biomedical

Advanced

Research and

Development

Authority

Special Projects

EP-IDS-

15-002

The work performed under this cooperative agreement

will directly benefit the public and expedite the

development of novel medical countermeasures.

Objective 1: An expert analysis of the potential role of

nontraditional antibacterial therapies (mAbs,

immunomodulatory and other host directed approaches,

phage, microbiome-oriented, etc.) in addressing the

threat of antimicrobial resistance and the challenges

facing the development of such products. Objective 2:

Expert assessment of financial incentives and business

models that could support MCM development for

emerging infectious diseases and uncertainties

concerning the threat they pose, and limited commercial

markets for MCMs against them.

9/4/15 Est. Total

Program

Funding:

$200,000

Award ceiling:

$200,000

Award floor:

$200,000

Unrestricted https://www

.grantsolutio

ns.gov/gs/pr

eaward/prev

iewPublicA

nnounceme

nt.do?id=54

377

14

PHS 2015-02

Omnibus

Solicitation of

the NIH, CDC,

FDA, and ACF

for Small

Business

Innovation

Research Grant

Applications

(Parent SBIR

[R43/R44])

PA-15-

269

Small business concerns that have the research

capabilities and technological expertise to contribute to

the R&D mission(s) of the NIH, CDC, FDA, or ACF

awarding components identified in this FOA are

encouraged to submit SBIR grant applications in these

areas. SBIR grant applications will also be accepted and

considered in any area within the mission of the

Components of Participating Organizations listed for

this FOA. Applicants are not required to identify a

potential awarding component prior to submission of the

application, but may request one in a cover letter. Staff

within the NIH’s Center for Scientific Review (CSR)

office, the single receiving point for all NIH, FDA,

CDC, and ACF grant applications, will assign all

applications to the most appropriate Agency

and Institute/Center (IC) based on their mission and the

science proposed.

4/5/16 Total direct and

indirect costs

may not exceed

$150,000 for

Phase I awards

and $1,000,000

for Phase II

awards.

Congress may

allow awards to

exceed these

amounts by up

to 50%

($225,000 for

Phase I and

$1,500,000 for

Phase II).

Small

Businesses

http://grants

.nih.gov/gra

nts/guide/pa

-files/PA-

15-

269.html?ut

m_source=

Announce&

utm_campai

gn=90bcd76

aa1-

Omnibus_R

eminder_E

mail+Blast_

July&utm_

medium=em

ail&utm_ter

m=0_fc108

5e209-

90bcd76aa1

-19347549

Secondary

Analysis of

Existing

Databases in

Traumatic Brain

Injury to

Explore

Outcomes

Relevant to

Medical

Rehabilitation

(R21)

RFA-

HD-16-

001

The purpose of this funding opportunity announcement

(FOA) is to support secondary analyses of existing

databases that have been established from clinical trials,

survey studies, or natural histories in traumatic brain

injury (TBI). These databases offer opportunities to

explore questions about survival, progression,

rehabilitation and recovery.

Letter of

Intent:

9/30/15

Full

submission:

10/30/15

Est. Total

Program

Funding:

$1,500,000

Award ceiling:

$200,000

Unrestricted http://grants

.nih.gov/gra

nts/guide/rfa

-files/RFA-

HD-16-

001.html